AEOLUS PHARMACEUTICALS INC
SymbolAOLS

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Data Demonstrating Aeolus Pharmaceuticals’ AEOL 10150’s Efficacy as a Broad Spectrum Countermeasure Against Radiological and Chemical Threats Presented at the GHSI Public Health Emergency Medical Countermeasures Workshop

2009-11-05 09:44 ET - News Release


MISSION VIEJO, Calif. -- (Business Wire)

Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today the presentation of data at the GHSI Public Health Emergency Medical Countermeasures Workshop detailing the potential of AEOL 10150 as a broad spectrum medical countermeasure (MCM) to treat radiological and chemical threats. Data presented from studies sponsored by Aeolus, the National Institutes of Health (NIH), National Institutes of Allergies and Immunological Disorders and NIH CounterACT, highlighted AEOL 10150’s efficacy in animal models of Acute Radiation Syndrome (ARS), sulfur mustard gas and chlorine gas exposure.

AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage via signaling cascades induced by radiation or chemical exposure. The compound’s mitigation of organ-specific damage induced by acute exposure to potentially lethal doses of radiation and chemical agents is based on the hypothesis, and supporting data, that these stressors initiate a pro-inflammatory cascade that disrupts organ integrity and function in a radiation or chemical dose- and time-dependent fashion. This common mechanism of action permits analysis of efficacy in multiple models of organ-specific damage. Research is focused on the use of validated animal models and research design compliant with the criteria of the FDA Animal Rule and development of a clear path to licensure by the FDA.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.